Cancer · 1992 · 42 citations · 12 references
MedicineOncologyPharmacotherapyCancer PharmacologyChemotherapyMedical OncologyMalignant NeoplasmsTherapy Response AssessmentToxicity ManagementChemotherapy Dose-limiting ToxicityDose-limiting Toxicity AssessmentIfosfamide-based TherapyMesothelioma Systemic TherapyPartial Response AssessmentPhase Ii InvestigationSystemic Drug TherapyTumor Response Evaluation
BACKGROUND: Malignant mesothelioma is a highly treatment-resistant neoplasm. This study represents an attempt to define an effective form of systemic therapy. METHODS: Twenty-six patients with unresectable diffuse malignant mesothelioma were enrolled in Southwest Oncology Group (SWOG) study 8731 and treated with ifosfamide, 2 g/m2 intravenously for 4 days, and mesna 2 g/m2 intravenously for 5 days, every 3 weeks. Patients were either previously untreated with chemotherapy or had at most one prior systemic treatment. RESULTS: Two patients, or 8% (95% confidence interval, 1-25%), achieved partial response, with response durations of 4 and 6 months. One additional patient met criteria for tumor size reduction but not duration criteria. Thirteen (50%) patients had stable disease of 4 months' median duration (range, 1-13 months). The median survival of the entire group was 6.5 months. The dose-limiting toxicity was granulocytopenia (11 patients, < or = 250/microliters). CONCLUSIONS: Ifosfamide/mesna has modest activity in malignant mesothelioma. It could be tested using alternate dosage schedules and in combination with other agents in treating this highly resistant neoplasm.
12
Ifosfamide in experimental tumor systems.
Abraham Goldin · PubMed · 1982 · 103 citations
Medicine, Oncology, Pharmacology +6
Phase II trial of carboplatin in the management of malignant mesothelioma.
Derek Raghavan, Peter Gianoutsos, J. Bishop et al. · Journal of Clinical Oncology · 1990 · 83 citations
Medicine, Oncology, Pharmacology +11
Michael K. Samson, Larry P. Wasser, Ernest C. Borden et al. · Journal of Clinical Oncology · 1987 · 77 citations
Medicine, Oncology, Pharmacology +13
Richard Woodman, Alphonse E. Sirica, M Gang et al. · Chemotherapy · 2009 · 68 citations
Medicine, Oncology, Pharmacology +11